Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.

Drögemöller BI, Wright GEB, Shih J, Monzon JG, Gelmon KA, Ross CJD, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group.

Breast Cancer Res Treat. 2018 Nov 8. doi: 10.1007/s10549-018-5027-0. [Epub ahead of print] Review.

PMID:
30411242
2.

A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.

Biliouris K, Nestorov I, Naik H, Dai D, Xiao G, Wang Q, Pellerin A, Rabah D, Lesko LJ, Trame MN.

J Pharmacokinet Pharmacodyn. 2018 Dec;45(6):817-827. doi: 10.1007/s10928-018-9609-6. Epub 2018 Oct 30.

PMID:
30377889
3.

Establishing a Multidisciplinary Framework to Study Drug-Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate.

Lesko LJ, Vozmediano V, Brown JD, Winterstein A, Zhao P, Lippert J, Höchel J, Chaturvedula A, White A, Schmidt S.

CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):706-708. doi: 10.1002/psp4.12357. Epub 2018 Oct 23.

4.

Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities.

Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep 25. doi: 10.1002/psp4.12353. [Epub ahead of print]

5.

A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.

Biliouris K, Gaitonde P, Yin W, Norris DA, Wang Y, Henry S, Fey R, Nestorov I, Schmidt S, Rogge M, Lesko LJ, Trame MN.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):581-592. doi: 10.1002/psp4.12323. Epub 2018 Aug 16.

6.

Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products.

Cristofoletti R, Rowland M, Lesko LJ, Blume H, Rostami-Hodjegan A, Dressman JB.

J Pharm Sci. 2018 Oct;107(10):2519-2530. doi: 10.1016/j.xphs.2018.06.013. Epub 2018 Jun 20.

PMID:
29935299
7.

Regulatory Perspectives in Pharmacometric Models of Osteoporosis.

Madrasi K, Li F, Kim MJ, Samant S, Voss S, Kehoe T, Bashaw ED, Ahn HY, Wang Y, Florian J, Schmidt S, Lesko LJ, Li L.

J Clin Pharmacol. 2018 May;58(5):572-585. doi: 10.1002/jcph.1071. Epub 2018 Feb 27. Review.

PMID:
29485684
8.

To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs.

Deng J, Brar SS, Lesko LJ.

Clin Pharmacol Drug Dev. 2018 Jun;7(5):455-464. doi: 10.1002/cpdd.416. Epub 2017 Dec 2.

PMID:
29197167
9.

Efficacy From Strange Sources.

Lesko LJ.

Clin Pharmacol Ther. 2018 Feb;103(2):253-261. doi: 10.1002/cpt.916. Epub 2017 Dec 1.

PMID:
29052220
10.

Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials.

Sharma VD, Combes FP, Vakilynejad M, Lahu G, Lesko LJ, Trame MN.

J Clin Pharmacol. 2018 Feb;58(2):240-253. doi: 10.1002/jcph.994. Epub 2017 Aug 31.

11.

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.

Lesko LJ, Offman E, Brew CT, Garza D, Benton W, Mayo MR, Romero A, Du Mond C, Weir MR.

J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):434-446. doi: 10.1177/1074248417691135. Epub 2017 Feb 13.

12.

Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now.

Weitzel KW, Cavallari LH, Lesko LJ.

Pharm Res. 2017 Aug;34(8):1551-1555. doi: 10.1007/s11095-017-2163-x. Epub 2017 May 2. Review.

13.

Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine.

Shaik AN, Altomare DA, Lesko LJ, Trame MN.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 1;1046:243-249. doi: 10.1016/j.jchromb.2016.11.027. Epub 2016 Nov 23.

PMID:
28162967
14.

Improving drug safety with a systems pharmacology approach.

Schotland P, Bojunga N, Zien A, Trame MN, Lesko LJ.

Eur J Pharm Sci. 2016 Oct 30;94:84-92. doi: 10.1016/j.ejps.2016.06.009. Epub 2016 Jun 7.

PMID:
27287422
15.

Systems pharmacology to predict drug safety in drug development.

Trame MN, Biliouris K, Lesko LJ, Mettetal JT.

Eur J Pharm Sci. 2016 Oct 30;94:93-95. doi: 10.1016/j.ejps.2016.05.027. Epub 2016 May 29. Review.

PMID:
27251780
16.

How Informative Are Drug-Drug Interactions of Gene-Drug Interactions?

Lagishetty CV, Deng J, Lesko LJ, Rogers H, Pacanowski M, Schmidt S.

J Clin Pharmacol. 2016 Oct;56(10):1221-31. doi: 10.1002/jcph.743. Epub 2016 Apr 26.

PMID:
27040602
17.

Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.

Jiang XL, Samant S, Lewis JP, Horenstein RB, Shuldiner AR, Yerges-Armstrong LM, Peletier LA, Lesko LJ, Schmidt S.

Eur J Pharm Sci. 2016 Jan 20;82:64-78. doi: 10.1016/j.ejps.2015.10.024. Epub 2015 Oct 30.

18.

Are We Getting the Best Return on Investment From Clinical Drug-Drug Interaction Studies?

Lesko LJ, Lagishetty CV.

J Clin Pharmacol. 2016 May;56(5):555-8. doi: 10.1002/jcph.661. Epub 2015 Dec 14. No abstract available.

PMID:
26470760
19.

Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).

Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, Lesko LJ, Gong Y.

J Bone Miner Res. 2016 Feb;31(2):336-40. doi: 10.1002/jbmr.2693. Epub 2015 Sep 4.

20.

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.

Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC; CPNDS Clinical Recommendation Group.

Ther Drug Monit. 2015 Aug;37(4):428-36. doi: 10.1097/FTD.0000000000000192. Review.

Supplemental Content

Loading ...
Support Center